Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties

Journal of Medicinal Chemistry

Volumn 55, Issue 6, 2012, Pages 2869-2881

  Mathieu, Simon ^a   Gradl, Stefan N ^a   Ren, Li ^b   Wen, Zhaoyang ^a   Aliagas, Ignacio ^a   Gunzner Toste, Janet ^a   Lee, Wendy ^a   Pulk, Rebecca ^a   Zhao, Guiling ^a   Alicke, Bruno ^a   Boggs, Jason W ^a   Buckmelter, Alex J ^b   Choo, Edna F ^a   Dinkel, Victoria ^b   Gloor, Susan L ^b   Gould, Stephen E ^a   Hansen, Joshua D ^b   Hastings, Gregg ^b   Hatzivassiliou, Georgia ^a   Laird, Ellen R ^b   Moreno, David ^b   Ran, Yingqing ^a   Voegtli, Walter C ^b   Wenglowsky, Steve ^b   Grina, Jonas ^b   Rudolph, Joachim ^a   more..

^a GENENTECH INC   (United States)

^b ARRAY BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO THIENO 3,2 D PYRIMIDINE 7 CARBOXYLIC ACID 2,6 DIFLUORO 3 PROPANE 1 SULFONYLAMINO PHENYL AMIDE; 4 AMINO THIENO 3,2-D PYRIMIDINE 7 CARBOXYLIC ACID 6 CHLORO 2 FLUORO 3 3 FLUORO PROPANE 1 SULFONYLAMINO PHENYL AMIDE; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG EXPOSURE; DRUG SOLUBILITY; MELANOMA; NONHUMAN; PHYSICAL CHEMISTRY; STOMACH PH; XENOGRAFT;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS B-RAF; QUINAZOLINES; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84863386955     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300016v     Document Type: Article

References (17)

1. Peyssonnaux, C.; Eychene, A. The Raf/MEK/ERK pathway: new concepts of activation Biol. Cell 2001, 93, 53-62 (Pubitemid 33040860)
2. Wan, P. T.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 2004, 116, 855-867 (Pubitemid 38410730)
3. Cohen, Y.; Xing, M.; Mambo, E.; Guo, Z.; Wu, G.; Trink, B.; Beller, U.; Westra, W. H.; Ladenson, P. W.; Sidransky, D. BRAF mutation in papillary thyroid carcinoma J. Natl. Cancer Inst. 2003, 95, 625-627 (Pubitemid 36553510)
4. Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P. N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; Burton, E. A.; Wong, B.; Tsang, G.; West, B. L.; Powell, B.; Shellooe, R.; Marimuthu, A.; Nguyen, H.; Zhang, K. Y. J.; Artis, D. R.; Schlessinger, J.; Su, F.; Higgins, B.; Iyer, R.; D'Andrea, K.; Koehler, A.; Stumm, M.; Lin, P. S.; Lee, R. J.; Grippo, J.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; Chapman, P. B.; Flaherty, K. T.; Xu, X.; Nathanson, K. L.; Nolop, K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 2010, 467, 596-599
5. Flaherty, K. T.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; O'Dwyer, P. J.; Lee, R. J.; Grippo, J. F.; Nolop, K.; Chapman, P. B. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma N. Engl. J. Med. 2010, 363, 809-819
6. Another selective B-Raf inhibitor in advanced clinical studies is dabrafenib (GSK2118436, GlaxoSmithKline) Kefford, R.; Arkenau, H. T.; Brown, M. P.; Millward, M.; Infante, J. R.; Long, G. V.; Ouellet, D.; Curtis, M.; Lebowitz, P. F.; Falchook, G. S. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors J. Clin. Oncol. 2010, 28 (15 Suppl (May 20 Supplement)) 8503
7. Wenglowsky, S.; Ren, L.; Ahrendt, K. A.; Laird, E. R.; Aliagas, I.; Alicke, B.; Buckmelter, A. J.; Choo, E. F.; Dinkel, V.; Feng, B.; Gloor, S. L.; Gould, S. E.; Gross, S.; Gunzner-Toste, J.; Hansen, J. D.; Hatzivassiliou, G.; Liu, B.; Malesky, K.; Mathieu, S.; Newhouse, B.; Raddatz, N. J.; Ran, Y.; Rana, S.; Randolph, N.; Risom, T.; Rudolph, J.; Savage, S.; Selby, L. T.; Shrag, M.; Song, K.; Sturgis, H. L.; Voegtli, W. C.; Wen, Z.; Willis, B. S.; Woessner, R. D.; Wu, W.-I.; Young, W. B.; Grina, J. Pyrazolopyridine Inhibitors of B-RafV600E. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors ACS Med. Chem. Lett. 2011, 2, 342-347
8. Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K.; Sproesser, K.; Li, L.; Smalley, K. S. M.; Fong, D.; Zhu, Y.-L.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S.-H.; Schlessinger, J.; Zhang, K. Y. J.; West, B. L.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P. N.; Hirth, P.; Artis, D. R.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 3041-3046 (Pubitemid 351723664)
9. Flaherty, K.; Puzanov, I.; Sosman, J.; Kim, K.; Ribas, A.; McArthur, G.; Lee, R. J.; Grippo, J. F.; Nolop, K.; Chapman, P. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer J. Clin. Oncol. 2009, 27 (15S (May 20 Supplement)) 9000
10. Vasconcelos, T.; Sarmento, B.; Costa, P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs Drug Discovery Today 2007, 12, 1068-1075 (Pubitemid 350186132)
11. V600E. Part 3: An increase in aqueous solubility via the disruption of crystal packing Bioorg. Med. Chem. Lett. 2012, 22, 912-915
12. Brameld, K. A.; Kuhn, B.; Reuter, D. C.; Stahl, M. Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis J. Chem. Inf. Model. 2008, 48, 1-24 (Pubitemid 351271046)
13. Furet, P.; Caravatti, G.; Guagnano, V.; Lang, M.; Meyer, T.; Schoepfer, J. Entry into a new class of protein kinase inhibitors by pseudo ring design Bioorg. Med. Chem. Lett. 2008, 18, 897-900 (Pubitemid 351179358)
14. Zhang, G.; Ren, P.; Gray, N. S.; Sim, T.; Liu, Y.; Wang, X.; Che, J.; Tian, S.-S.; Sandberg, M. L.; Spalding, T. A.; Romeo, R.; Iskandar, M.; Chow, D.; Seidel, H. M.; Karanewsky, D. S.; He, Y. Discovery of pyrimidine benzimidazoles as Lck inhibitors: Part I Bioorg. Med. Chem. Lett. 2008, 18, 5618-5621
15. Ohkubo, A.; Kasuya, R.; Miyata, K.; Tsunoda, H.; Seio, K.; Sekine, M. New thermolytic carbamoyl groups for the protection of nucleobases Org. Biomol. Chem. 2009, 7, 687-694
16. V600E. Part 2: Structure-activity relationships Bioorg. Med. Chem. Lett. 2011, 21, 5533-5537
17. Chu, K. A.; Yalkowsky, S. H. Predicting aqueous solubility: the role of crystallinity Curr. Drug Metab. 2009, 10, 1184-1191